← 返回

肺癌细胞内在 IL-15 促进细胞迁移并使小鼠肺肿瘤对抗 PD-L1 治疗敏感

英文原题:Lung cancer cell-intrinsic IL-15 promotes cell migration and sensitizes murine lung tumors to anti-PD-L1 therapy.

查看英文原题

Lung cancer cell-intrinsic IL-15 promotes cell migration and sensitizes murine lung tumors to anti-PD-L1 therapy.

PubMed 2024/04/19(内容时间) Biomark Res Q1 · IF 14.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

癌细胞内在的 IL-15 与外源性 IL-15 对细胞运动和迁移的调控存在差异。

中文摘要

IL-15可增强NK细胞和T细胞介导的抗肿瘤免疫应答,但IL-15对肿瘤细胞的直接作用尚未充分阐明。本研究调查IL-15对肺腺癌细胞的影响。

采用敲低和过表达技术调节肿瘤细胞内源性IL-15表达。通过Transwell实验评估肿瘤细胞迁移和侵袭;利用活细胞分析系统评估细胞运动能力;采用共聚焦荧光显微镜量化形态变化;通过Western blot分析IL-15对肿瘤细胞作用的分子机制,并采用pulldown实验评估RhoA和Cdc42活性。使用NCG和C57BL/6小鼠模型评估IL-15体内功能。

癌细胞内源性IL-15通过活化AKT-mTORC1通路,促进体外细胞运动和迁移以及体内转移;而外源性IL-15则通过抑制RhoA-MLC2轴,抑制细胞运动和迁移。机制分析显示,细胞内和细胞外IL-15介导的效应均需要肿瘤细胞表达IL-15R。进一步分析发现,在细胞内IL-15与IL-15R形成的复合物中,未检测到IL-2/IL-15Rβ链和IL-2Rγ链;但外源IL-15作用于肿瘤细胞后,会形成包含IL-15Rα、IL-2/IL-15Rβ和IL-2Rγ链的复合物,提示细胞内和细胞外IL-15对肿瘤细胞的不同作用可能源于IL-15受体结合方式不同。利用Lewis肺癌(LLC)转移模型,研究显示IL-15过表达虽促进LLC细胞肺转移,但与野生型IL-15 LLC肿瘤相比,IL-15过表达LLC肿瘤对抗PD-L1治疗更敏感;其依据是抗肿瘤免疫应答增强,表现为CD8⁺ T细胞浸润增加。

癌细胞内源性IL-15与外源性IL-15对细胞运动和迁移的调节作用不同,因此内源性IL-15在肿瘤进展中可能是一把双刃剑。此外,肿瘤细胞高表达IL-15可能提高肿瘤对免疫治疗的应答。

展开英文摘要原文

IL-15 plays a vital role in enhancing NK cell- and T-cell-mediated antitumor immune responses; however, the direct effect of IL-15 on tumor cells has not been fully elucidated. Herein, we investigated the effect of IL-15 on lung adenocarcinoma cells.

Silencing and overexpression techniques were used to modify endogenous IL-15 expression in tumor cells. Transwell assays were used to assess tumor cell migration and invasion; a live-cell analysis system was used to evaluate cell motility; cellular morphological changes were quantified by confocal fluorescence microscopy; the molecular mechanisms underlying the effect of IL-15 on tumor cells were analyzed by western blotting; and RhoA and Cdc42 activities were evaluated by a pulldown assay. NCG and C57BL/6 mouse models were used to evaluate the functions of IL-15 in vivo.

Cancer cell-intrinsic IL-15 promoted cell motility and migration in vitro and metastasis in vivo via activation of the AKT-mTORC1 pathway; however, exogenous IL-15 inhibited cell motility and migration via suppression of the RhoA-MLC2 axis. Mechanistic analysis revealed that both the intracellular and extracellular IL-15-mediated effects required the expression of IL-15R by tumor cells. Detailed analyses revealed that the IL-2/IL-15R and IL-2R chains were undetected in the complex formed by intracellular IL-15 and IL-15R . However, when exogenous IL-15 engaged tumor cells, a complex containing the IL-15R , IL-2/IL-15R , and IL-2R chains was formed, indicating that the differential actions of intracellular and extracellular IL-15 on tumor cells might be caused by their distinctive modes of IL-15 receptor engagement. Using a Lewis lung carcinoma (LLC) metastasis model, we showed that although IL-15 overexpression facilitated the lung metastasis of LLC cells, IL-15-overexpressing LLC tumors were more sensitive to anti-PD-L1 therapy than were IL-15-wild-type LLC tumors via an enhanced antitumor immune response, as evidenced by their increased CD8 + T-cell infiltration compared to that of their counterparts.

Cancer cell-intrinsic IL-15 and exogenous IL-15 differentially regulate cell motility and migration. Thus, cancer cell-intrinsic IL-15 acts as a double-edged sword in tumor progression. Additionally, high levels of IL-15 expressed by tumor cells might improve the responsiveness of tumors to immunotherapies.

论文信息

作者
Hu S、Meng K、Wang T、Qu R、Wang B、Xi Y、Yu T、Yuan Z
第一作者单位
Thoracic Surgery Laboratory, Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie Fang Avenue, 430030, Wuhan, Hubei, China.China
通讯作者单位
Thoracic Surgery Laboratory, Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie Fang Avenue, 430030, Wuhan, Hubei, China. lqli@tjh.tjmu.edu.cn.China
期刊
Biomarker research2024 Apr 19
原文标识
PubMed 38637902 · DOI 10.1186/s40364-024-00586-w